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Cost-effectiveness of an Ineffective Therapy(?)
In the June issue of the Journal, Pedretti et al. (1) presented
an innovative study on the cost-effectiveness of different
tests to select postinfarct patients for amiodarone therapy.
However, as the accompanying editorial (2) pointed out, the
“cost-effectiveness of these tests can be no better than the
cost-effectiveness of the therapies prescribed based on their
results.” To this end, I think the conclusion reached in this
paper is weak and may be misleading for readers of this
journal.
Amiodarone has not been shown to improve overall
survival in post-MI patients. Only a meta-analysis (3),
which has important limitations, suggests a possible benefit.
The analyses in the present study relied entirely on the data
from EMIAT and CAMIAT trials, which did not show an
overall improvement in survival. No tests can be cost-
effective if the treatment selected is not. Using amiodarone
as a sole therapy in this high-risk group of patients,
especially those with a positive EP study, is clinically
unrealistic and renders the accompanying analyses irrele-
vant.
On the other hand, implantable defibrillators (ICDs)
have been shown to improve overall survival in two pub-
lished (MADIT and AVID) (4,5) and two unpublished
(CIDS and CASH) prospective randomized controlled
trials. Unfortunately, the use of ICDs as an alternative to
amiodarone was not emphasized by Pedretti et al. (1) or in
the accompanying editorial (2). Had the authors included
this proven therapy as a treatment option in their study,
invasive strategy with EP studies may turn out to be
cost-effective simply because of the effectiveness of ICD and
its superiority over amiodarone (4,5).
The conclusions reached by Pedretti et al. (1) at best
provide little clinically useful information and at worst are
potentially misleading. Because an inferior treatment was
chosen for analysis, it is not surprising that invasive electro-
physiology studies did not prove to be cost-effective. By
omitting to include ICDs as a treatment option and by
failing to discuss this important limitation, this study does
the readers of this journal a disservice by undermining the
true utility of electrophysiology studies in selecting patients
for appropriate treatment (4). I believe that the publication
of this paper, sets us back a full decade in our practice of
clinical electrophysiology.
James J. C. Ong, MD, FACC, FCCP
Tarzan, California
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REPLY
Dr Ong expressed some criticism concerning our recent
paper (1).
Results of base-case analysis showed that amiodarone
improved survival in recent post-MI patients with low heart
rate variability at an incremental cost between $20,000 and
$40,000/additional QALY which is consistent with other
currently founded programs, such as hemodialysis or treat-
ment of mild hypertension with diuretic drugs or propran-
olol. In our model, this acceptable incremental cost-
effectiveness ratio derived from a 17% amiodarone-induced
reduction in total mortality at two years, which is similar to
the significant survival benefit observed in a recent pub-
lished meta-analysis (2). Sensitivity analysis showed similar
cost-effectiveness ratios in other subgroups of patients
selected by different noninvasive testing, but not in those
with CAMIAT and EMIAT screening criteria. These data
902 Letters to the Editor JACC Vol. 33, No. 3, 1999
March 1, 1999:897–903
agree with CAMIAT and EMIAT findings, do not support
a systematic prophylactic use of amiodarone in post-MI
patients, but suggest a potential benefit for the drug at an
acceptable cost in different subgroups at high risk of
arrhythmias. To our knowledge, these findings provide
relevant, realistic and clinically useful information.
Asymptomatic patients who have positive noninvasive
and electrophysiologic testing after a recent MI are at very
high risk of arrhythmic death, with a relatively low risk of
nonsudden death. It is in these patients that an antiarrhyth-
mic intervention has the greatest potential to improve
outcome and amiodarone is an effective antiarrhythmic drug
because it reduced arrhythmic mortality between 33% and
45% in CAMIAT and EMIAT trials. Thus, it is relevant,
realistic and clinically useful to compare the “two-level” with
the more simple noninvasive approach in terms of cost-
effectiveness ratio in this therapeutic scenario. Obviously,
such an analysis is appropriate also with the ICD as a
therapy, and would be very intriguing because ability of the
ICD to abort sudden death is no longer in question.
Unfortunately, it is impossible to provide good answers to
multiple questions in a single study. Moreover, all available
data about ICD effectiveness are relative to patients with
late post-MI or who suffered from symptomatic ventricular
tachycardia or were resuscitated from cardiac arrest (3).
These findings may not be a priori extended to recent
post-MI asymptomatic patients, like those included in our
model. Some ICD studies ongoing or recently started will
provide in the next few years a definitive answer about the
capability of the ICD in improving overall survival in recent
post-MI patients.
Roberto F. E. Pedretti, MD, FESC
Fondazione Salvatore Maugeri, Care and Research Institute
Division of Cardiology, Rehabilitation Institute
Via Roncaccio, 16, I-21049, Tradate (VA), Italy
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